Back to News
Market Impact: 0.34
CRAI Stock Rises 12.4% in Three Months: Here's What You Should Know
Source: zacks.com
Corporate Guidance & OutlookCompany FundamentalsCapital Returns (Dividends / Buybacks)Healthcare & Biotech
Charles River is benefiting from broad-based demand and margin expansion, while raising its fiscal 2026 revenue outlook. The company also continues to return capital to shareholders, reinforcing a favorable operating and capital-allocation outlook.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.58
Ticker Sentiment
CRL0.78
More News
- Europe’s winter energy crunch may already be underway. Two U.S. stocks that may benefit
- Broadcom to lend Anthropic up to $42 billion to lease its chips, filing says
- $8.2B acquisition validates AI-picked chip stock: +20% since June
- Nike Warns Sales Slump Will Worsen This Fiscal Year
- Nuveen CEO on Schroders Deal, Plans for Combined Company
- New Mexico wants Meta to pay up to $40 billion in penalties after data privacy trial